cas 1021260-20-7|| where to buy 1-{[2-(2-ethoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-5-methyl-N-(2,4,6-trimethylphenyl)-1H-1,2,3-triazole-4-carboxamide

Nombre del producto:1-{[2-(2-ethoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-5-methyl-N-(2,4,6-trimethylphenyl)-1H-1,2,3-triazole-4-carboxamide

IUPAC Name:1-{[2-(2-ethoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-5-methyl-N-(2,4,6-trimethylphenyl)-1H-1,2,3-triazole-4-carboxamide

Unidad de embalaje	Stock disponible	Precio($)	Cantidad

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1021260-20-7 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1021260-20-7; Fórmula molecular:C26H29N5O3; Punto de fusión:-; Código de sonrisas:CCOC1=C(C=CC=C1)C1=NC(CN2N=NC(C(=O)NC3=C(C)C=C(C)C=C3C)=C2C)=C(C)O1; Densidad:

: Número de catálogo:CM800645; Peso molecular:459.55; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Oxazoles; Oxazoles are heterocyclic aromatic compounds containing one oxygen atom and one nitrogen atom, separated by a carbon atom. The presence of two heteroatoms (oxygen and nitrogen) provides possible interactions (hydrogen, hydrophobic, van der Waals or dipole bonds) with a wide range of receptors and enzymes. Oxazole rings are valuable heterocyclic scaffolds for the design of novel therapeutics with anticancer, antiviral, antibacterial, anti-inflammatory, neuroprotective, antidiabetic, and antidepressant properties due to their wide range of targets and biological activities.

: Triazoles; Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.